XBP1 and neoplasm: This strategy paves the way for new immunotherapies targeting XBP1, with the potential to improve prognosis in ovarian cancer and other aggressive tumors, by simultaneously reducing tumor cell survival and restoring an effective antitumor immune microenvironment [326].